{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:13:45Z","timestamp":1769724825689,"version":"3.49.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/gme.0b013e3182755c97","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T12:27:07Z","timestamp":1356956827000},"page":"504-510","source":"Crossref","is-referenced-by-count":29,"title":["Overexpression of progesterone receptor membrane component 1"],"prefix":"10.1097","volume":"20","author":[{"given":"Hans","family":"Neubauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Schneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benfor","family":"Mafuvadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman M.","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred O.","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210211","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women.","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R2-6-20210211","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy.","volume":"291","year":"2004","journal-title":"JAMA"},{"key":"R3-6-20210211","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.295.14.1647","article-title":"Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.","volume":"295","author":"Stefanick","year":"2006","journal-title":"JAMA"},{"key":"R4-6-20210211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsbmb.2007.12.002","article-title":"HRT and breast cancer caused: caused by progestogens Experimental vs. clinical data.","volume":"109","author":"Seeger","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R5-6-20210211","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study.","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R6-6-20210211","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0960-0760(95)00215-4","article-title":"Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: 1. MCF-7 cell lines.","volume":"55","author":"Schoonen","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R7-6-20210211","first-page":"2551","article-title":"Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines.","volume":"15","author":"Cappelletti","year":"1995","journal-title":"Anticancer Res"},{"key":"R8-6-20210211","first-page":"139","article-title":"The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells.","volume":"27","author":"Kramer","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod"},{"key":"R9-6-20210211","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bjc.1993.175","article-title":"Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.","volume":"67","author":"Catherino","year":"1993","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"R10-6-20210211","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.maturitas.2003.09.019","article-title":"Differential effects of progestogens on breast cancer cell lines.","volume":"46","author":"Franke","year":"2003","journal-title":"Maturitas"},{"key":"R11-6-20210211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2007.02.002","article-title":"Progesterone receptor membrane component 1: an integrative review.","volume":"105","author":"Cahill","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R12-6-20210211","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1432-1033.1996.0726u.x","article-title":"Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes.","volume":"239","author":"Meyer","year":"1996","journal-title":"Eur J Biochem"},{"key":"R13-6-20210211","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/17425255.2012.658367","article-title":"S2R(Pgrmc1): the cytochrome-related -2 receptor that regulates lipid and drug metabolism and hormone signaling.","volume":"8","author":"Ahmed","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R14-6-20210211","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/bcr2155","article-title":"Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.","volume":"10","author":"Neubauer","year":"2008","journal-title":"Breast Cancer Res"},{"key":"R15-6-20210211","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/13697130802635637","article-title":"Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.","volume":"3","author":"Neubauer","year":"2009","journal-title":"Climacteric"},{"key":"R16-6-20210211","first-page":"903","article-title":"Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer.","volume":"76","author":"Peluso","year":"2011","journal-title":"Steroids"},{"key":"R17-6-20210211","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1074\/mcp.M600046-MCP200","article-title":"Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.","volume":"6","author":"Munton","year":"2007","journal-title":"Mol Cell Proteomics"},{"key":"R18-6-20210211","doi-asserted-by":"crossref","first-page":"24775","DOI":"10.1074\/jbc.M110.134585","article-title":"PGRMC1 (progesterone receptor membrane component 1) associates with EGFR and regulates erlotinib sensitivity.","volume":"285","author":"Ahmed","year":"2010","journal-title":"Biol Chem"},{"key":"R21-6-20210211","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/gme.0b013e31820e5ac5","article-title":"The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells.","volume":"18","author":"Neubauer","year":"2011","journal-title":"Menopause"},{"key":"R23-6-20210211","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3109\/09513590.2012.671396","article-title":"Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells.","volume":"28","author":"Ruan","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"R24-6-20210211","doi-asserted-by":"crossref","first-page":"9929","DOI":"10.1158\/0008-5472.CAN-07-1103","article-title":"Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.","volume":"67","author":"Liang","year":"2007","journal-title":"Cancer Res"},{"key":"R25-6-20210211","first-page":"1","article-title":"The role of progestogens in breast cancer: experimental vs. clinical data.","volume":"14","author":"Mueck","year":"2006","journal-title":"Menopausal Med"},{"key":"R26-6-20210211","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/dmi046","article-title":"New progestogens for contraceptive use.","volume":"12","author":"Sitruk-Ware","year":"2006","journal-title":"Hum Reprod Update"},{"key":"R27-6-20210211","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.maturitas.2004.01.001","article-title":"Pharmacological profile of progestins.","volume":"47","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"issue":"Suppl 1","key":"R28-6-20210211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration.","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric"},{"key":"R29-6-20210211","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/AOG.0b013e31818e8cd6","article-title":"Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.","volume":"113","author":"Lyytinen","year":"2009","journal-title":"Obstet Gynecol"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/gme.0b013e3182755c97","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:36:31Z","timestamp":1620977791000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201305000-00006"}},"subtitle":["possible mechanism for increased breast cancer risk with norethisterone in hormone therapy"],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3182755c97","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}